HUALIN PHARMACEUTICAL-B (STOCK CODE: 2552) WILL HOLD ITS ANNUAL GENERAL MEETING ON 27 JUNE 2024 AT THE HEADQUARTERS OF THE COMPANY (BUILDING 2, BLOCK 36 SHULIN ROAD, SHULIN ROAD, PUDONG NEW DISTRICT, SHANGHAI, CHINA). The meeting will include the review of the 2023 audited consolidated financial statements, the Board's report and auditor's report, and the re-election of executive and non-executive directors such as Mr. Chen Li, Ms. Zhang Yi. In addition, the meeting will renew the appointment of Tak Kin Guan Huang Chan Fang Accountant to act as the company's auditor and authorize the Board of Directors to determine his remuneration. Shareholders will vote on whether to grant the directors general authority to repurchase and issue shares and consider the adoption of new articles of association. Shareholders may appoint representatives to vote at the General Meeting and the proxy form must be submitted by 25 June 2024. The Company's share transfer registration will be suspended from 24 to 27 June 2024.

HUALIN PHARMACEUTICAL-B (STOCK CODE: 2552) WILL HOLD ITS ANNUAL GENERAL MEETING ON 27 JUNE 2024 AT THE HEADQUARTERS OF THE COMPANY (BUILDING 2, BLOCK 36 SHULIN ROAD, SHULIN ROAD, PUDONG NEW DISTRICT, SHANGHAI, CHINA). The meeting will include the review of the 2023 audited consolidated financial statements, the Board's report and auditor's report, and the re-election of executive and non-executive directors such as Mr. Chen Li, Ms. Zhang Yi. In addition, the meeting will renew the appointment of Tak Kin Guan Huang Chan Fang Accountant to act as the company's auditor and authorize the Board of Directors to determine his remuneration. Shareholders will vote on whether to grant the directors general authority to repurchase and issue shares and consider the adoption of new articles of association. Shareholders may appoint representatives to vote at the General Meeting and the proxy form must be submitted by 25 June 2024. The Company's share transfer registration will be suspended from 24 to 27 June 2024.